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Recombinant antibodies are highly specific detection probes in research, diagnostics, and
have emerged over the last two decades as the fastest growing class of therapeutic pro-
teins. Antibody generation has been dramatically accelerated by in vitro selection systems,
particularly phage display. An increasing variety of recombinant production systems have
been developed, ranging from Gram-negative and positive bacteria, yeasts and filamentous
fungi, insect cell lines, mammalian cells to transgenic plants and animals. Currently, almost
all therapeutic antibodies are still produced in mammalian cell lines in order to reduce the
risk of immunogenicity due to altered, non-human glycosylation patterns. However, recent
developments of glycosylation-engineered yeast, insect cell lines, and transgenic plants are
promising to obtain antibodies with “human-like” post-translational modifications. Further-
more, smaller antibody fragments including bispecific antibodies without any glycosylation
are successfully produced in bacteria and have advanced to clinical testing. The first ther-
apeutic antibody products from a non-mammalian source can be expected in coming next
years. In this review, we focus on current antibody production systems including their
usability for different applications.
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INTRODUCTION
Today, antibodies are used for several applications in research,
diagnostics, and therapy. They are used in many standard assays
such as immunoblot, flow cytometry, or immunohistochemistry.
In addition this, the emerging field of proteome research has a
huge need of binders against different protein antigens and splice
variants (1, 2). Moreover, recombinant antibodies are used for
the diagnosis of different pathogens (3–5) or toxins (6, 7). In
the past decade, several antibodies for therapeutic applications
have been developed (8, 9), primarily targeting inflammatory or
tumor diseases (10). In 2010, sales of approved therapeutic mon-
oclonal antibodies in the USA and EU reached 50 billion US
dollars (11).
For the detection of different antigens,polyclonal antibodies are
widely used in research and diagnostics. These sera contain a large
and diverse amount of different antibodies with unknown speci-
ficities. However, polyclonal non-human antibodies may exhibit
an immune response in human beings that hampers the therapeu-
tic use for example after snake bites (12). Therefore, the production
of monoclonal antibodies (mAbs) by hybridoma technology was
a significant milestone (13) for the generation of antibodies for
therapeutic use. As this technology is based on the fusion of
antibody producing spleen cells from immunized mice or rats
with immortal myeloma cell lines, its main obstacle is the inef-
ficient immune response to highly toxic or conserved antigens.
In addition, nearly all antibodies which are currently in clini-
cal development are of human-origin or at least humanized in
some aspect (9, 14, 15) to prevent immunogenicity. Consequently,
Abbreviations: IgG, immunoglobulin G; mAb, monoclonal antibody.
transgenic animals, especially mice, have been developed which
contain a human immunoglobulin gene repertoire (16, 17) solving
the problem of immunogenicity but not the need of an efficient
immune response after immunization. Finally, in vitro selection
technologies such as antibody phage display or ribosomal dis-
play provide a solution for the generation of human antibodies
(18–22).
These new antibody generation technologies have increased the
amount of antibodies for different applications and, therefore, also
the need of efficient production systems. Immunoglobulin G (IgG)
is a heterotetrameric molecule consisting of two heavy and two
light chains, respectively, which are connected via disulfide bonds.
Heavy and light chains (HC and LC) also contain intramolecular
disulfide bonds for stabilization (23). These structural properties
require a sophisticated folding apparatus as well as an oxidizing
environment for the generation of disulfide bonds. Consequently,
many traditionally expression hosts do not provide these mecha-
nisms for efficient production of IgGs. Therefore, smaller antibody
fragments have been developed which combine easier production
with full antigen binding capacity of an IgG (Figure 1). In addition,
the development of smaller fragments was the basis for most of
the in vitro antibody generation systems (18–22). These antibody
fragments can be used for applications, where epitope binding is
sufficient for the desired effect including therapeutic applications
such as virus neutralization or receptor blocking.
The smallest antigen binding fragment of immunoglobulins
maintaining its complete antigen binding site is the Fv fragment,
which consists only of variable (V) regions. A soluble and flex-
ible amino acid peptide linker is used to connect the V regions
to a scFv (single chain fragment variable) fragment for stabi-
lization of the molecule (24), or the constant (C) domains are
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FIGURE 1 | Recombinant antibody formats for different applications
compared to IgG. Red and dark red: variable regions; blue: constant
regions; green: artificial peptide linkers; yellow: dHLX represents
amphiphatic helices used for dimerization of scFv fragments.
added to the V regions to obtain a Fab fragment (Figure 1).
Today, scFv and Fab are the most widely used antibody fragments
which are produced in prokaryotes. Other antibody formats have
been produced in prokaryotic and eukaryotic cells, for example,
disulfide-bond stabilized scFv (ds-scFv) (25), single chain Fab
fragments (scFab) combining scFv and Fab properties (26) as
well as di- and multimeric antibody formats like dia-, tria-, or
tetra-bodies (27, 28) or minibodies (miniAbs) comprising differ-
ent formats consisting of scFvs linked to oligomerization domains
like immunoglobulin CH3 domain (28), leucin zipper, helix turn
helix motif streptavidin, or scFv-scFv tandems (29–31). Bispecific
antibody formats combine two different antigen binding domains
in one molecule (32–34). The smallest antibody fragments are
VHHs of cameloide heavy chain antibodies (35) and single domain
antibodies (dAb) (36, 37).
For most therapeutic applications, the Fc moiety of an
immunoglobulin is essential for the method of action as it medi-
ates the effector functions such as cellular dependent cytotoxicity
or the activation of the complement system. Therefore, antibody
fragments have been fused to the Fc domain to regain effector func-
tions and avidity (38, 39). Figure 1 depicts some of these antibody
formats that have been developed for different applications.
ANTIBODY PRODUCTION IN PROKARYOTIC HOSTS
GRAM-NEGATIVE BACTERIA
Escherichia coli is the most important production system for
recombinant proteins reaching volumetric yields in the gram per
liter scale for extracellular production (40–42). For production of
functional antibody fragments, the key to success was the secre-
tion of both V chains into the periplasmic space of E. coli where
the oxidizing environment allows the correct formation of disul-
fide bonds and the assembly to a functional Fv fragment (43).
This strategy also allowed the first expression of functional Fab
fragments in E. coli described in 1988 (44).
The production of recombinant antibodies in the reducing
cytoplasmic compartment results mostly in non-functional aggre-
gates (45). Recovery of functional antibody fragments from cyto-
plasmic inclusion bodies by complete denaturation and refolding
(46) is often not efficient. Stable cysteine free mutants of some
scFvs were successfully produced in the cytoplasm of E. coli (47,
48). E. coli strains with mutations in the glutathione and thiore-
doxin reductase in combination with coexpression of cytoplasmic
chaperones GroEL/ES, trigger factor, DnaK/J as well as signal
sequence-less variants of periplasmic chaperones DsbC and Skp
increased the yield of functional Fab (49).
For the production of camelid single domain antibodies
(VHH), coexpression of Erv1p sulfhydryl oxidase increased the
yield in the cytoplasm (50).
Despite these efforts, most antibody fragments are produced
in the periplasm of E. coli using N-terminal leader sequences
targeting the periplasmic Sec pathway (51), for example signal
peptides derived from outer membrane protein A (OmpA), alka-
line phosphatase A (PhoA), or pectate lyase B (PelB) (52–54). Also
the SRP pathway can be used for antibody fragment production
(55). After expression, recombinant antibodies are usually isolated
from the periplasmic fraction (56, 57) but also from the culture
supernatant (58–61).
The yield of functional scFv fragments has been improved
by co- or overexpression of GroES/L, peptidyl prolyl-cis,trans-
isomerase FkPa, or other folding helper proteins (62–66). Func-
tional expression can also be increased by optimization of culti-
vation parameters, such as temperature, media, or additives. Here,
the optimal parameters are dependent on the individual antibody
fragment (58, 67). The production system itself influences the pro-
duction rate. Very high yields of antibody fragments produced in
E. coli are mainly provided by high-cell density fermentation in
bioreactors: the expression of a hapten-specific scFv produced in a
bioreactor (68) lead to yields up to 1.2 g/L compared to 16.5 mg/L
yield of the same antibody obtained by optimized shake flask pro-
duction (69), which can be mostly addressed to the over 100-fold
higher cell density in the bioreactor. A recent production system
is the LEX bubble column bioreactor. Yields in the LEX system
of an anti-MUC1 scFv was ∼30–40× higher and yields of an
anti-lysozyme antibody was about 2× higher compared to shake
flask incubation (67, 70). E. coli strain optimization, e.g., plasmid
stability, can additionally improve production yield (71).
The Fab format requires expression, periplasmic transport, cor-
rect folding, and assembly of two different polypeptide chains.
Among the different vector formats and arrangements, bicistronic
vectors with the first cistron encoding the light chain and the
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second cistron encoding the Fd fragment are optimal (56). Even
aglycosylated full-size IgGs were successfully produced in E. coli
(72, 73). In our view, the raison d’être of complete IgG production
in E. coli is doubtful.
Cell wall-less L-forms of the Gram-negative bacterium Proteus
mirabilis were used for the production of miniAbs and scFv (30,
74), but yield of total scFv and of functional scFv were different
and ranged from 83 to 127 mg/L of total scFv to just 9–12 mg/L of
functional scFv (74). However, quite recently scFv were produced
successfully in Pseudomonas putidas with a yield of 0.5–3.6 mg/L.
Interestingly, production yields were decreased by using scFv genes
codon optimized for P. putidas (75).
GRAM-POSITIVE BACTERIA
Gram-positive bacteria directly secrete proteins into the medium
due to the lack of an outer membrane which could facilitate
production of antibody fragments. The Gram-positive bacteria
Bacillus brevis (76, 77), Bacillus subtilis (78, 79), and Bacillus
megaterium (80–85) have already been successfully used for the
production of different antibody fragments. In addition, B. mega-
terium does not produce alkaline proteases and provides high sta-
bility of plasmid vectors during growth allowing stable transgene
expression during long term cultivation in bioreactors (86).
Lactobacilli are also tested for antibody production and are
“generally regarded as safe” (GRAS) microorganisms. To date, two
lactobacillus strains were used for the production of scFvs, Lacto-
bacillus zeae/casei (87,88),and Lactobacillus paracasei (35,89). The
GRAS status of lactobacilli allows their direct use for oral appli-
cation for example for production of anti-Streptococcus mutans
antibody fragments to prevent tooth decay (88).
EUKARYOTIC HOSTS USED FOR ANTIBODY PRODUCTION
YEASTS
Eukaryotic cells have developed an advanced folding, post-
translational, and secretion apparatus which enhances the secre-
tory production of antibodies, including full immunoglobulins
compared to bacteria. Yeasts combine the properties of eukaryotic
cells short generation time and ease of genetic manipulation with
the robustness and simple medium requirements of unicellular
microbial hosts. Moreover, yeasts have been used for fermentation
in food production for several millennia in human history; they
do not produce bacterial endotoxins and have gained the GRAS
status paving the way toward production of therapeutic proteins
(90, 91). Pichia pastoris represents the major yeast strain used
for recombinant antibody production (92). Other yeasts like Sac-
charomyces cerevisiae, Hansenula polymorpha, Schizosaccharomyces
pombe (93, 94), Schwanniomyces occidentalis, Kluyveromyces lactis,
and Yarrowia lipolytica (95) have also been described for protein
production but have played only a minor role. P. pastoris shows
overall optimal capacity for the production and secretion of het-
erologous proteins than S. cerevisiae and does not secrete large
amounts of its own protein which simplifies the downstream pro-
cessing. Moreover, P. pastoris prefers respiratory growth resulting
in high-cell densities of more than 100 g/L dry weight (96). Proba-
bly the most prominent feature of P. pastoris is the metabolization
of methanol as sole carbon source. The alcohol oxidase 1 (AOX1)
promoter is strictly controllable by methanol and commonly used
for recombinant protein expression. The secretory production of
heterologous proteins including antibodies requires an aminoter-
minal signal sequence targeting the yeast’s secretory pathway. S.
cerevisiae mating factor alpha (alpha-factor) pre-pro peptide is
the most commonly used secretory signal sequence and is fol-
lowed by appropriate proteolytic cleavage sites sensitive for the
Golgi resident endoprotease KEX2 for efficient release of antibod-
ies during secretion, which is often used in combination with ST13
exoprotease sites (97).
Expression of scFv antibody fragments in P. pastoris was first
shown by Ridder et al. in 1995 (98). Yields for different scFvs
ranged from 70 mg/L (99) to 250 mg/L (100). Up to 8 g/L func-
tional scFv were obtained under optimized conditions in bioreac-
tors with coexpression of BiP (101). Llama VHHs achieved over
100 mg/L yield in S. cerevisiae even in shake flask cultivation (102).
Production of more complex,yet still single-gene-encoded formats
such as dimeric scFv-Fc antibodies in P. pastoris achieved produc-
tion levels of 10–30 mg/L (103). Antibody formats encoded by two
genes such as Fab and IgG required the fusion of the two different
antibody chains to the aminoterminal secretory signal sequence
and their cotransformation. The yield of Fabs produced in yeast
ranged from 1 to 50 mg/L by shake flask cultivation and up to
0.5 g/L in bioreactors (96).
Limited data concerning full-sized IgG expression in yeast is
available. In an early study, a mouse-human chimeric antibody
and its Fab fragment were produced in S. cerevisiae with a yield of
50–80µg/L IgG and 200µg/L Fab, respectively. The chimeric IgG
mediated tumor specific binding and ADCC (antibody dependent
cellular cytotoxicity) but no CDC (complement dependent cyto-
toxicity) (104). Using P. pastoris up to 1.4 g/L of a human IgG1
could be expressed in a 40-L bioreactor (105).
Lower transformation rates compared to E. coli must be con-
sidered for antibody library generation rather than for antibody
production. Moreover, the frequency of homologous transforma-
tion in yeast is higher compared to higher eukaryotes facilitating
the process of making stable expression clones. Specific issues
of heterologous protein expression in yeast can be circumvented
by optimizing gene sequences, for example by avoiding AT-rich
stretches which can cause premature transcriptional termination.
The productivity of antibody fragments in yeasts was increased by
DNA shuffling (106).
Inefficient secretion of larger heterologous proteins (>30 kDa),
proteolysis of secreted proteins during high-cell density fermenta-
tion, and inappropriate glycosylation of human glycoproteins are
serious issues which required engineering of yeast strains. Overex-
pression of the chaperone immunoglobulin binding protein (BiP)
or protein disulfide isomerase (PDI) in S. cerevisiae increased
scFv secretion titers twofold to eightfold, with an average yield
of 20 mg/L in shake flask culture (107). Yeasts tend to hypergly-
cosylate heterologous proteins even at positions not glycosylated
in the native mammalian host, which can influence activity of
antibodies and is a potential source of immunogenicity or adverse
reactions in human patients. P. pastoris exhibits much lower hyper-
glycosylation than S. cerevisiae, and its N -linked carbohydrate
structures are already similar to the mammalian high-mannose
core unit Man5–6GlcNAc2 (108). Moreover, genetically modified
glyco-engineered P. pastoris strains have been generated which
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produce humanized glycosylation patterns (109–113). The thera-
peutic IgG antibodies produced in glyco-engineered yeast achieved
results that were comparable to its counterpart Trastuzumab that
has been produced in mammalian cells (114). Unlike IgGs pro-
duced in wildtype yeast, those produced in glyco-engineered yeasts
were able to mediate antibody-mediated effector functions. Pro-
duction processes employing glyco-engineered yeasts are currently
optimized for commercial antibody production (115) as well as for
high throughput screening (116).
FILAMENTOUS FUNGI
Filamentous fungi of the genera Trichoderma and Aspergillus have
the capacity to secrete large amounts of proteins and metabolites
into the medium (117). They are widely used in the food and
biotechnological industry, for example A. niger for citric acid pro-
duction. Moreover,A. niger (subgenus A. awamori) and Aspergillus
oryzae gained obtained GRAS status. Two promoters are typically
used for the expression of antibodies in fungi: the glucoamylase
promoter (glaA) (118) and the endoxylanase A promoter (exlA)
(119). Antibody chains are usually fused to the aminoterminus
of glucoamylase in Aspergillus and cellobiohydrolase I in Tri-
choderma spec., respectively, in order to obtain optimal secretion
(120). Moreover, protease cleavage sites like KexB are introduced
to release the antibody from glucoamylase before secretion (118).
Yields of up to 1.2 g/L IgG were achieved in A. niger when both
antibody chains were fused to glycoamylase. In Trichoderma reesei,
150 mg/L of a Fab fragment was obtained when both chains were
fused with cellobiohydrolase I increasing yields 100-fold higher
than with its natural signal peptide (121). A. awamori was used for
the production of several scFvs, llama VHHs and antibody enzyme
fusion proteins (117, 119, 122). A yield of 73.8 mg/L of an anti-
EGFR-VHH was achieved in A. oryzae by using a Taka-amylase
A signal sequence and 28 amino acids from the aminoterminal
region of Rhizopus oryzae lipase (123).
Fungal proteases can result in protein degradation which was
addressed by deletion mutants. Chrysosporium lucknowense C1
contains a triple protease deletion (Delta-alp1, Delta-pep4, Delta-
alp2) and was successfully used in small-scale productions for
screening as well as in high scale bioreactor productions (124).
PROTOZOA
Recently, the eukaryotic parasite Leishmania tarentolae has been
explored as an expression system for different recombinant pro-
teins (125, 126). One major advantage of this expression system
is the mammalian-like glycosylation pattern: this protozoa is able
to perform O-glycosylation as well as N-glycosylation, which is
highly conserved in mammalians (127). Consequently, L. tarento-
lae has been begun to be used for the production of recombinant
antibodies: analysis of different signal peptides lead to a protein
yield of 2–6 mg/L purified scFv (128).
INSECT CELLS
Insect cells represent a very versatile eukaryotic expression sys-
tem. They can be efficiently transfected with insect-specific viruses
from the family of Baculoviridae, particularly the Autographa cal-
ifornica nuclear polyhedrosis virus (AcNPV). Baculoviruses are
highly species-specific and are considered as safe for humans,
mammalians and plants. Infection of human hepatocytes and
mammalian cell lines including stable transduction has been
demonstrated in cell culture without evidence of viral replication
or gene expression under the control of baculoviral promoters
(129, 130). Non-essential baculovirus genes involved in the viral
life cycle, like Polyhedrin, P10, or Basic can be replaced by heterol-
ogous genes. The flexible viral envelop allows packaging of large
heterologous gene sequences of more than 20 kb. Heterologous
genes under the control of the strong polyhedron promoter are
expressed at levels ranging from 0.1 to 50% of the total insect cell
protein. Baculoviral protein expression is normally performed in
insect cell lines like Sf-9 and Sf-21 of Spodoptera frugiperda, DS2
cells of Drosophila melanogaster, or High Five cells (BTI-TN-5B1-
4) of Trichopulsia ni. High Five cells have certain advantages over
Sf-9 cells for recombinant protein expression because they secrete
up to 25-fold higher protein levels (131), have a more rapid dou-
bling time, allow quick adaptation to serum-free medium and
grow in suspension culture. In contrast, Sf-9 and Sf-21 cells are
recommended for producing high-titer viral stocks due to higher
transfection efficiency. Recombinant protein production can be
performed in small-scale using plates or shake flasks as well as in
large scale using Spinner flasks or bioreactors. Important parame-
ters for optimizing baculoviral protein production are multiplicity
of infection (m.o.i.), production length (usually up to 96 h), addi-
tion of protease inhibitors due to the release of viral proteases,
temperature (usually 25–30°C), and media pH (pH 6.0–6.4).
Secreted monomeric anti-phOx scFv were obtained at levels
of up to 32 mg/L in a 6-L bioreactor with 109 cells per liter after
72 h with an m.o.i. of 1 (132). Production yields of 6–18 mg/L have
been achieved for various IgGs (133). Immunoglobulins produced
in High Five cells showed mammalian-like terminal galactosyl
residues β(1,4)-linked to the biantennary GlcNAc residues. In
contrast, the absence of sialylation, the formation of paucimanno-
sidic structures and the presence of potentially allergenic α(1,3)-
fucose linkages are different to mammalian glycosylation (134).
Nevertheless, IgGs produced in insect cells were able to mediate
effector functions like complement binding (135, 136) and ADCC
(137). Insect cell protein expression was improved using protease
deficient baculovirus strains or cell lines with additional glyco-
syltransferase gene modifications to obtain glycosylation patterns
comparable to mammalian cell lines (138–141).
Expression of IgGs in insect cells under control of the
strong Polyhedron promoter resulted in an extensive aggrega-
tion, probably caused by overloading the cellular folding and
post-translational processing apparatus (142).
Overexpression of the ER resident chaperone binding protein
(BiP) significantly enhanced levels of soluble and secreted IgGs in
T. ni cells (143). Enhanced secretion of IgGs was also achieved by
coexpression of protein disulfide isomerase (PDI) or the human
cytosolic chaperone hsp70 in T. ni cells (138).
Due to strong usage of the cellular metabolism during baculovi-
ral protein expression a high diversity in the post-translational
modification was observed. Alternatively to baculoviral expres-
sion, insect cells can also be transfected with expression plasmids
in a transient or stable manner. Here, usually Schneider 2 (S2) cells
of D. melanogaster are used. Secretory production requires a sig-
nal sequence like the honeybee melittin leader. Stable transfection
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of Drosophila cell lines with monomeric and dimeric antibody
fragments resulted in yields of up to 25µg/mL (144).
Immunoglobulin G production using the baculovirus expres-
sion system demonstrated IgG effector function such as comple-
ment binding (135, 136). 10µg/mL of anti-Rhesus D antibody
produced in Sf-9 cells mediated lysis of Rh+ red blood cells by
ADCC (137).
MAMMALIAN CELLS
Today, 60–70% of all recombinant protein pharmaceuticals and
95% of the currently approved therapeutic antibodies are still
produced in mammalian cell lines despite relatively high pro-
duction costs and difficult in handling. However, the advanced
mammalian folding, secretion and post-translational apparatus
is capable of producing antibodies indistinguishable from those
in the human body with least concerns for immunogenic mod-
ifications. Moreover, it is also highly efficient for secretion of
large and complex IgGs and in combination with the folding
and post-translational control it results in high product quality
which reduces efforts and costs in the subsequent and more expen-
sive downstream processing steps. The risks of contamination
by pathogens or bovine spongiform encephalopathy (TSE/BSE)
agents have been eliminated by well-documented Good Manu-
facturing Practice (GMP) compliant designer cell substrates and
chemical defined media without the need of supplementing ani-
mal serum components (145). In 2004, mammalian cell culture
technology reached production levels of approximately 5 g/L IgGs
in Chinese hamster ovary (CHO) cells (146). Today, industrial
IgG production levels often exceed 12 g/L as the result of a steadily
ongoing progress in mammalian cell culture technology, which is
mainly due to improved high producer cell lines, optimized pro-
duction media, and prolonged production processes at high-cell
densities. The highest reported IgG production titer we found was
obtained in the human embryonic retinal cell line Per.C6 [Crucell,
Leiden, Netherlands, (147)] with 27 g/L. Generally, the productiv-
ity of recombinant mammalian cell lines increased from initially
10 pg antibody per cell per day (pcd) in 1986 to about 90 pcd
in 2004. Today, the antibody production levels only rarely exceed
100 pcd because higher cellular productivity usually corresponds
to lower maximum cell densities in the production process. Pro-
ducer cell lines have also been genetically engineered regarding
product homogeneity, improved metabolism, reduced apoptosis,
and inducible cell cycle arrest (148, 149) which allows prolonged
production times for almost 3 weeks at high-cell viability and cell
densities.
Chinese hamster ovary (CHO) cells are the most common
cells applied in the commercial production of biopharmaceuti-
cals. This cell line isolated in the 1950s gave rise to a range of
genetically different progeny, such as K1-, DukX B11-, DG44-
cell lines and others which differ in protein product quality and
achievable yield. In addition, Per.C6 cells, mouse myeloma NS0
cells, baby hamster kidney (BHK) cells and the human embry-
onic kidney cell line HEK293 received regulatory approval for
recombinant protein production. Although glycosylation patterns
of mammalian glycoproteins are very similar to that in humans
(150), even small differences can influence pharmacokinetics and
effector functions of antibodies. Alternative designer cell lines with
improved glycosylation patterns have been generated, for exam-
ple human neuronal precursor cell line AGE1.HN (Probiogen,
Berlin, Germany) supporting specific and complex glycostructures
for the production of antibodies which require specific post-
translational modifications or suffer from instability or suscep-
tibility for proteolysis (151). CHO cell variant Lec13 (Glycotope)
also produces human IgG1 with N -Linked glycans lacking fucose
which improves on Fc-gammaRIII binding and ADCC (152).
Stable production of antibodies in mammalian cells
The generation of stable master cell lines is a prerequisite for GMP
compliant IgG production in the therapeutic sector in order to
guarantee long term production stability. Here, the antibody gene
expression cassettes have to be stably integrated into the host cell
genome.
Strong promoters like the immediate early cytomegalovirus
(CMV) or the cellular elongation factor (EF) 1-alpha promoter
and polyadenylation sites from the simian virus (SV) 40 or the
bovine growth hormone (BGH) for improved mRNA stability and
translation efficiency are usually implemented into the expres-
sion vector. Furthermore, splicing of mRNA is known to promote
mRNA packaging and transfer into the cytosol in order to sta-
bilize and enhance gene expression as well as to reduce silencing
of heterologous transgenes (153, 154). For IgG expression, two
different genes must be stably transfected into one cell clone,
either by cotransfection or by using bicistronic expression vec-
tors. Bicistronic vectors employing internal ribosomal entry sites
(IRES) allow the translation of two or more cistrons from the
same transcript (155). The encephalomyelitis virus (ECMV) IRES
has shown the highest efficiency in various mammalian cell lines.
Mutated IRES derivatives allow the control of translation effi-
ciency in relation to the cap-dependent cistron. The ratio between
light and heavy chain has great impact on the secretion level of
functional IgGs (156). The long term stability of ECMV IRES
containing bicistronic constructs has been demonstrated even in
the absence of selection pressure over months (157).
There are different methods to enhance antibody expression
by increasing the number of antibody gene copies in the genome
through gene amplification. The two major systems on the market
are based on dihydrofolate reductase (DHFR) or glutamyl syn-
thetase (GS) selection.Yield and functionality of an IgG1 produced
in dhfr− CHO and GS-NSO are equivalent (158) and reached
1.8 g/L in GS-NS0 cells (159). However, gene amplification also
causes genetic instability, and after removing the selection pres-
sure the yield of antibodies can be reduced again. Moreover,
high producer cell lines often contain only a few copies of the
antibody genes. For example, up to 2.7 g/L final antibody con-
centration were obtained from NS0 cells containing three vector
copies per cell (160). Other factors than the number of gene
copies play an important role to achieve high production levels
of antibodies. Therefore, industrial antibody expression platforms
employ efficient screening systems in order to isolate the best of
the high producers. However, there are also strategies to facil-
itate the isolation of high producer clones (161). To overcome
negative effects of the integration site, protective cis-regulatory
elements include insulators, boundary elements, scaffold/matrix
attachment regions (S/MARs) (162), chromatin opening elements
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(163), and antirepressor elements (164) were introduced into the
vector which reduced the influence of heterochromatin and sta-
bilize transgene expression (165, 166). Silencing can be blocked
by inhibition of histone deacetylation using butyrate (167) which
could enhance the protein expression levels of the cells (168) but
can also induce apoptosis.
Recombination enzymes, like bacteriophage P1 Cre recombi-
nase, lambda phage integrase, or yeast Flp recombinase can effi-
ciently catalyze the site specific integration into defined chromo-
somal recombination exchange cassettes which have been intro-
duced into producer cell lines (169, 170). The 2A/furin technology
allows expression of both IgG chains as a single gene due to
post-translational auto-cleavage of the viral protease 2A encoded
by the linker and subsequent processing by the Golgi protease
furin (171, 172).
Transient production of antibodies in mammalian cells
The generation of high producer cell lines has been dramati-
cally improved and accelerated (161, 173), however it is still too
expensive, time-consuming and laborious for research applica-
tions, or if large numbers of individual antibodies have to be
produced. Here, transient and semi-stable mammalian antibody
expression is much more suitable because it allows fast and paral-
lelized production without any need to generate producer cell lines
(174). Moreover, transient mammalian antibody production can
be scaled up by employing batch or fed-batch bioreactor processes
to more than 150 L production volumes (175). Therefore, tran-
sient antibody production is suitable for small-scale production
in antibody screening (176), but also capable to generate grams of
antibodies (177–179).
The human embryonic kidney (HEK) 293 cell lines have been
widely used for transient protein expression because they can be
very efficiently transfected with plasmid DNA. Some derivatives
were further transformed either with the simian virus 40 (SV40)
large T antigen, termed HEK293T, or with the Epstein Barr virus
(EBV) nuclear antigen 1 (EBNA1), termed HEK293E, in order
to mediate semi-stable episomal propagation of vectors contain-
ing an origin of replication (ori) of SV40 or EBV, respectively.
Transient transfection of plasmid DNA in HEK293 cells can also
be performed in large scale by calcium phosphate transfection
(180), cationic liposomes, and polymers like polyethyleneimine
(PEI) (181, 182).
Recently, transient production of IgG-like scFv-Fc antibodies
in the HEK293-6E cell line, a genetically modified variant with a
truncated version of EBNA1 growing in suspension and chemically
defined serum-free medium (183, 184), achieved volumetric yields
of up to 0.6 g/L by simple shake flask cultivation. Improved pro-
duction media, fed-batch supplementation, and well-controlled
bioreactor processes allow higher cell densities and prolonged pro-
duction time, both enhancing the yield. Backliwal and colleagues
(177) combined optimized PEI-based transfection at high-cell
densities with the coexpression of cell cycle regulators p18 and
p21,acidic fibroblast growth factor,valproic acid supplementation,
consequent maintenance at high-cell densities of cells/milliliter
and up-scaling to 2 L and achieved production levels of more than
1 g IgG within 2 weeks after transient transfection.
TRANSGENIC ORGANISMS
TRANSGENIC PLANTS
The development of transgenic plants for the expression of recom-
binant antibodies is becoming interesting, especially when high
amounts are required. Up-scaling of this production system can
be achieved more easily compared to other systems such as mam-
malian cell culture, where up-scaling of the fermentation process
leads to increasing production costs. In theory, the costs of an IgA
expressed in plants are only 1–10% compared to the expression in
hybridoma cells (185).
The generation of genetically modified dicotyledonous plants is
mainly done by the transfer of the expression cassette of the trans-
gene with the help of Agrobacterium tumefaciens. In principle, the
gene of interest is cloned into the T-DNA of a binary plasmid (186,
187) which is flanked by two 25 bp imperfect repeats. In most cases,
the expression of the transgene is under the control of one or two
(188) copies of the constitutive cauliflower mosaic virus (CaMV).
In addition, a selection marker is located on the T-DNA and trans-
ferred into the host genome for effective screening of successfully
transformed plants. After integration of the T-DNA into the host
genome by non-homologous recombination complete plants can
be regenerated from transformed pieces of the plant [RB (189)].
As this procedure requires several months of transformation and
special regeneration protocols, transient expression systems have
been developed which allow time saving production of recom-
binant proteins: McCormick and colleagues designed a tobacco
mosaic virus (TMV) based vector for the secretory expression
of different scFvs for the treatment of non-Hodgkin’s lymphoma
(190). Expression yields in Nicotiana benthamiana were up to 100–
800µg/mL in the crude secretory extract. Same technique has been
applied for the expression of idiotype-scFvs for personalized vac-
cination of follicular B-cell lymphoma patients in a phase I clinical
study (191). In this study, nearly half of the treated patients devel-
oped an antigen specific immune response despite differences in
glycosylation pattern.
Differences in the glycosylation pattern between mammalia and
plants are one of the main obstacles researchers have to over-
come when developing therapeutic antibodies expressed in plants.
Although plants are able to perform complex glycosylation, differ-
ences in glycosylation patterns, in particular β1,2-xylose and α1,3-
fucose, can lead to immunogenicity of the therapeutic proteins
(192–194). Therefore, different strategies have been developed to
express recombinant proteins with a more mammalian-like gly-
cosylation pattern. The first one is the retention of the protein in
the endoplasmic reticulum (eR) as eR-associated N-glycosylation
leads to the generation of oligomannose-type N -glycans which
are identical in plants and mammalians (192, 195). One side effect
of this localization is the accumulation to higher levels in the
eR (196, 197). A second approach for the expression of proteins
with mammalian-like glycosylation patterns is the usage of glyco-
engineered plants. In most cases, RNA interference (RNAi) is used
for the down-regulation of endogenous beta1,2-xylosyltransferase
and alpha1,3-fucosyltransferase leading to a reduction of the xylo-
sylated and core-fucosylated N -glycans (198–200). A second type
of glyco-engineering in plants is the coexpression of genes which
facilitates the expression of human-like N -glycans (201) or even
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the in planta protein sialylation by the coexpression of six mam-
malian genes (202). An increasing effort has been put into the
adaptation of N-glycosylation, but there are also some efforts in
the engineering of sialylated mucin-type O-glycans to achieve
the most human-like glycosylation patterns (203, 204). Alter-
natively, non-glycosylated antibodies which mediate protection
against an inhalation anthrax spore challenge in non-human pri-
mates showed an improvement of the half-life in serum (205).
Rodriguez and colleagues showed that the aglycosylated form of
Nimotuzumab (currently in a phase II clinical study in the USA
and Canada) produced in tobacco shares the in vitro and in vivo
properties as well as the antitumor effect in nude mice with the
glycosylated form (206).
Transient expression of an antibody in plants can be achieved
using viral vectors. The main problem with this approach is the
low infectivity with these vectors. Therefore, the more efficient
transfer of A. tumefaciens was combined with the speed and high
expression rate of plant RNA viruses (207). This system has been
used for the expression of monoclonal antibodies in Nicotiana
benthamiana with yields up to 0.5 g/kg fresh weight (208).
In principle, most plantibodies are expressed in tobacco (N.
tabacum or N. benthamiana), but there are also production sys-
tems in Lemna minor (duckweed) (209–211), rice cell culture
(212), Arabidopsis thaliana seeds (213, 214), Medicago sativa
(alfalfa) (215), lettuce (216), and maize (217). HIV-1 neutral-
izing antibody 2G12 was expressed in the endosperm of maize
and showed similar or even better neutralizing properties as its
CHO-derived counterpart (218).
Besides the transfection or transformation of whole plants or at
least organs, monoclonal BY-2 tobacco cell lines that grow in sus-
pension have been developed (219). Flow cytometric analysis has
been used to enrich cells expressing a fluorescent marker which
was located on the same T-DNA with the antibody gene. Using
this method for the enrichment of high expressing cells, produc-
tion could be increased up to 13-fold and was shown to be stable
for 10–12 months.
Much effort has been set into the establishment and devel-
opment of plants producing antibodies for therapy, but so far
none of these products has appeared on the market, despite of
the estimated dramatic reduction of production costs (220). Nev-
ertheless, at least two plant derived antibodies have been used
in clinical trials: CaroRX was developed by Planet Biotechnol-
ogy (Hayward, CA, USA) and is expressed in transgenic tobacco
(221). This antibody binds to the streptococcal antigen I/II of S.
mutans, the major causative agent of bacterial tooth decay and
prevents the attachment of S. mutans to tooth enamel. CaroRX
has entered clinical phase II (222, 223). A second plant-made anti-
idiotype antibody against non-Hodgkin-lymphoma (NHL) which
was successfully tested in clinical phase I study has been mentioned
above (191, 224).
TRANSGENIC ANIMALS
In recent years the idea of expressing human antibodies in trans-
genic animals has increased. On the one hand the humanization
of antibodies for therapeutics derived from hybridoma technol-
ogy is still a laborious and time-consuming procedure which often
requires the generation and characterization of a set of different
humanized versions of the antibody. On the other hand the mouse
or rat derived antibodies may elicit an immune response in patients
(225, 226). One method for the generation of fully human binders
is the antibody phage display technology (21).
Beside this, several researchers developed transgenic animals for
the production and expression of human monoclonal and poly-
clonal antibodies: therefore, human antibodies have mostly been
expressed in the milk of transgenic mice (227–230), goats (231),
or even in eggs of transgenic chickens (232).
The first step toward the generation of human antibodies in
animals by immunization was the transfer of a human minilo-
cus containing unrearranged immunoglobulin variable, diversity,
and joining elements linked to a human µ-chain into mice (233).
In this study, approximately 4% of the extracted B-lymphocytes
expressed human antibodies. The immunization of larger animals
containing human chromosomal immunoglobulin loci would
enable the production of even larger amounts of antibodies.
Therefore, transgenic cattle were developed by the transfer of a
human artificial chromosome vector containing the entire unre-
arranged sequences of the human immunoglobulin heavy and
lambda light chain loci (234). For the improvement of the human
antibody proportion and for safety reasons regarding the poten-
tial risk of BSE, the bovine immunoglobulin µ heavy chain locus
and the bovine prion protein have been knocked out (235, 236).
Finally, transgenic cattle carrying human immunoglobulin heavy
and kappa-light chain loci have been used for immunization
with anthrax protective antigen. The resulting polyclonal antibody
mixture consisted of entirely human and chimeric immunoglob-
ulins that showed high activity and were protective in an in vivo
mouse challenge models (237). Rabbits and cattle were used for
expression of a bispecific scFv targeting the melanoma-associated
proteoglycan and the human CD28 molecule on T cells (238). The
usage of different animals as a source for the generation of human
polyclonal sera has already been initiated: the immunoglobulin
gene loci have been knocked out in livestock such as pigs or rab-
bits (239–241). For a review of approaches for the generation of
transgenic animals expressing polyclonal human antibodies see
Houdebine (242).
Much of the energy in transgenic production has been set
on the development of humanized mice or rats. The well estab-
lished property of generating hybridoma cells from these species
facilitates a streamlined approach for the generation of a cell
line which stably expresses monoclonal antibodies (17, 243, 244).
Using humanized mice, an anti-HIV-1 gp140 antibody was identi-
fied, but in contrast the low number of antigen specific hybridomas
occurring during the generation of the clones has been observed
(245). Therefore, the usage of humanized rats has been sug-
gested to circumvent these problems and first antibodies have
been developed with sub-nanomolar affinities using the so called
OmniRat (246).
CONCLUDING REMARKS
Today, mammalian cell lines represent the most widely used
expression system for the production of recombinant antibodies.
Several other hosts are being developed which are even able to pro-
duce antibodies with human-like glycosylation patterns. In addi-
tion to this, there are several applications where the glycosylation
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Table 1 | Production of recombinant antibodies by host.
Host Antigen Antibody format
(clone)
Production
system
Yield Reference
GRAM-NEGATIVE BACTERIA
Escherichia coli Digoxin Fab (26–10) Shake flask 0.8 mg/L/OD600 Levy et al. (49)
Escherichia coli CD18 F (ab′)2 Fermentor 2.5 g/L Chen et al. (247)
Escherichia coli Lysozyme scFv (D1.3) 250/400 mL shake
flask
0.3–1.0 mg/L Jordan et al. (84), Monsellier and
Bedouelle (248), Thie et al. (70)
Escherichia coli CRP scFv (LA13-IIE3) 300 mL shake flask 0.55 mg/L Jordan et al. (83)
Escherichia coli Lysozyme scFab (D1.3) 300 mL shake flask 9.5µg/L
Escherichia coli MUC1 VHH 100 L shake flask 10 mg/L Rahbarizadeh et al. (249)
Escherichia coli Clostridium difficile
toxin A
VHH (14 different) Shake flask? 1.2–72.3 mg/L Hussack et al. (250)
Escherichia coli MUC1 scFv (2 different) 250 mL shake flask 0.46/1.3 mg/L Thie et al. (70)
Escherichia coli p815HER2 Fab 10 L fermenter 1–2 g/L Carter et al. (251)
Escherichia coli Atrazine Fab (K411B) 2 L fermenter 13.8 mg/L Wiebe et al. (66)
Escherichia coli PPL VL dAb 1.5 L fermenter 35–65 mg/L Cossins et al. (252)
Escherichia coli phOx scFv 50 mL shake flask 16.2 mg/L Kipriyanov et al. (69)
Escherichia coli phOx scFv 3 L fermenter 1.2 g/L Sletta et al. (68)
Escherichia coli Scorpion toxin Cn2 scFv; Fab (BCF2) n. d. 0.3 mg/L;
1.0 mg/L
Quintero-Hernández et al. (253)
Escherichia coli TNF alpha scFv Shake flask? 45 mg/L Yang et al. (254)
Escherichia coli HSP70 Fab (cmHsp70.1) 8 L fermenter >15 mg/L Friedrich et al. (64)
Escherichia coli Tissue factor IgG 10 L fermenter 130–150 mg/L Simmons et al. (73)
Escherichia coli TAG-72 Fv (B72.3) Shake flask;
fermentor
40 mg/L;
450 mg/L
King et al. (255)
Escherichia coli VEGF scFv::SUMO 50 mL shake flask? 50.3 mg/L Ye et al. (256)
Escherichia coli HIV capsid Fab, engineered Shake flask 12 mg/L Nadkarni et al. (257)
Escherichia coli Ovarian
carcinoma/CD3
scFv–scFv 250 mL shake flask 1.2 g/L Zhao et al. (71)
Escherichia coli Fibroblast growth
factor receptor FGFR1
VHH Shake flask 10–15 mg/L Veggiani and de Marco (50)
Escherichia coli Human prion scFv Shake flask 35 mg/L Padiolleau-Lefevre et al. (258)
Escherichia coli Lysozyme scFv (D1.3) LEX bioreactor (1.5 L) ∼2 mg/L Miethe et al. (67)
Escherichia coli MUC1 scFv (HT186-D11) LEX bioreactor (1.5 L) ∼40 mg/L
Escherichia coli CD30 scFv (SH313-B5) LEX bioreactor (1.5 L) ∼38 mg/L
Escherichia coli Crf2 scFv (MS112-IIB1) LEX bioreactor (1.5 L) ∼4.5 mg/L
Escherichia coli Tubulin scFv (different
ones)
Shake flask
(intracellular)
up to 50 mg/L Philibert et al. (259)
Escherichia coli n. d. Fab 20 L; 75 L fed-batch
bioreactor
0.7 g/L; 0.5 g/L Nesbeth et al. (260)
(Continued)
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Table 1 | Continued
Host Antigen Antibody format
(clone)
Production
system
Yield Reference
Proteus mirabilis FAP scFv (OS4) 50 mL shake flask ∼12 mg/L Rippmann et al. (74)
Proteus mirabilis Phosphorylcholine scFv-dHLX n. d. 10–18 mg/L Kujau et al. (30)
Pseudomonas
putidas
Lysozyme scFv (D1.3) 200 mL shake flask 1.5 mg/L Dammeyer et al. (75)
Pseudomonas
putidas
MUC1 scFv (HT186-D11) 200 mL shake flask 3.6 mg/L
Pseudomonas
putidas
CRP scFv (TOB5-D4) 200 mL shake flask 2.9 mg/L
GRAM-POSITIVE BACTERIA
Bacillus brevis uPA Fab 2 L shake flask 100 mg/L Inoue et al. (76)
Bacillus megaterium Lysozyme scFv (D1.3) 400 mL shake flask 0.41 mg/L Jordan et al. (84)
Bacillus megaterium CRP scFv (LA13-IIE3) 300 mL shake flask 0.39 mg/L Jordan et al. (83)
Bacillus megaterium Lysozyme scFab (D1.3) 300 mL shake flask 3.5µg/L Jordan et al. (83)
Bacillus subtilis Digoxin scFv n. d. 12 mg/L Wu et al. (78)
Lactobacillus
paracasei
Rotavirus VHH n. d. ∼1 mg/L Pant et al. (35)
Streptomyces
lividans
Lysozyme Fv n. d. ∼1 mg/L Ueda et al. (261)
EUKARYOTES
Yeast
Yarrowia lipolytica,
Kluyveromyces lactis
Ras scFv Shake flasks 10–20 mg/L Swennen et al. (262)
Pichia pastoris Muc1 VHH Baffled flasks 10–15 mg/L Rahbarizadeh et al. (263)
Pichia pastoris TNFα VHH-Fc Shake flasks 5 mg/L Ji et al. (264)
Pichia pastoris AaHI VHH Shake flasks 17 mg/L Ezzine et al. (265)
Pichia pastoris B-type natriuretic
peptide
scFv Shake flasks 150 mg/L Maeng et al. (266)
Pichia pastoris Atrazine Fab-HRP Shake flasks 3–10 mg/L Koliasnikov et al. (267)
Pichia pastoris Muc1 Bibody, tribody Shake flasks 12–36 mg/L Schoonooghe et al. (268)
Saccharomyces
cerevisiae
71 Different VHH Shake flasks <1 to
>100 mg/L
Gorlani et al. (269, 270)
Pichia pastoris HER2 scFv Shake flasks 15–20 mg/L Sommaruga et al. (271)
Pichia pastoris n. d. scFv n. d. 300 mg/L Khatri et al. (272)
Pichia pastoris Keratin 8 sc (Fv)2 Baffled shake flasks 4–5 mg/L Jafari et al. (273)
Pichia pastoris n. d. IgG 0.5 L bioreactor 0.5–1 g/L Barnard et al. (274)
Pichia pastoris Rabies virus scFv-Fc 80 L fermenter 60 mg/L Wang et al. (275)
Pichia pastoris HER2 IgG 3 L bioreactor 148–227 mg/L Chen et al. (276)
(Continued)
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Table 1 | Continued
Host Antigen Antibody format
(clone)
Production
system
Yield Reference
Filamentous fungi
Aspergillus niger var.
awamori
ErbB2 IgG, Fab Shake flasks 0.9 g/L; 0.2 g/L Ward et al. (118)
Aspergillus niger var.
awamori
Lysozyme scFv 7 L fermenter 108.9 mg/L Sotiriadis et al. (277)
Aspergillus oryzae EGFR VHH Shake flasks 73.8 mg/L Okazaki et al. (123)
Protozoa
Leishmania
tarentolae
16 Different scFv scFv Shake flasks 0.04–
3.38 mg/L
Klatt and Konthur (128)
Insect cells
Trichoplusia ni larvae Rotavirus VHH Living larvae 257 mg/L Gómez-Sebastián et al. (278)
Spodoptera
frugiperda
Blood coagulation
factor VIII
scFv Shake flasks 3.2–10 mg/L Kurasawa et al. (279)
Drosophila, S2 Glycoprotein H Fab Spinner flasks 16 mg/L Backovic et al. (280)
Drosophila, S2 HIV IgG n. d. 5–35 mg/L Johansson et al. (281)
Drosophila, S2 Bovine viral diarrhea
virus, hepatitis C virus
scFv n. d. 5–12 mg/L Gilmartin et al. (282)
Spodoptera
frugiperda, SF-9
gp41 IgG T-flasks 3 mg/L Palmberger et al. (283)
Trichoplusia ni gp41 IgG T-flasks 12 mg/L Palmberger et al. (283)
Sf SWT-1 Mimic gp41 IgG T-flasks 3 mg/L Palmberger et al. (283)
MAMMALIAN CELLS
Transient
HEK293T CD200, SIRPγ Fab Genejuice, roller
bottles
4 mg/L Nettleship et al. (284)
HEK293T n. d. IgG HEKfectin, tissue
culture plates
1–14 mg/L Li et al. (155)
CHO n. d. IgG1, IgG4 Lipofectamine 140 mg/L Codamo et al. (285)
HEK293F n. d. IgG 293fectin 100–400 mg/L Van Berkel et al. (286)
CHO DG44 RhD IgG PEI, square-shaped
bottles
90 mg/L Wulhfard et al. (287)
HEK293E n. d. IgG PEI, square-shaped
bottles
200 mg/L Backliwal et al. (288)
CHO n. d. IgG PEI, square-shaped
bottles
60–80 mg/L Wulhfard et al. (289)
HEK293E RhD IgG PEI, square-shaped
bottles
1.1 g/L Backliwal et al. (177)
Stable
CHO-K1 n. d. IgG Lipofectamine 0.05–
0.45 mg/L
Li et al. (155)
CHO HIV-1 scFv-Fc PEI 5.78–
45.49 mg/L
Mader et al. (290)
(Continued)
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Table 1 | Continued
Host Antigen Antibody format
(clone)
Production
system
Yield Reference
CHO n. d. IgG Electroporation 4 g/L Kober et al. (291)
NS0 n. d. IgG 5 L bioreactor,
fed-batch
800 mg/L Spens and Häggström (292)
NS0 n. d. IgG 2–100 L bioreactor 2.64 g/L Burky et al. (293)
per.C6 n. d. IgG Hollow fiber
bioreactor
1 g/L Jones et al. (147)
per.C6 n. d. IgG Roller bottle culture 50–100 mg/L Jones et al. (147)
per.C6 n. d. IgM Shake flasks 0.5–2 g/L Tchoudakova et al. (294)
CHO n. d. VHH-Fc Shake flasks 100 mg/L Agrawal et al. (295)
CHO HER2 IgG Orbital shaking
bioreactor
152 mg/L Huang et al. (296)
Transgenic plants
Chlamydomonas
reinhardtii
CD22 Immunotoxin,
exotoxin A
Particle
bombardement
0.2–0.4% of
chloroplasts
Tran et al. (297)
Nicotiana tabacum BoNT/A scFv Agrobacterium
tumefaciens
20–40 mg/kg Almquist et al. (298)
Nicotiana
benthamiana
HIV IgG CPMV 105.1 mg/kg Sainsbury et al. (299)
Nicotiana tabacum HCC scFv-RNase Agrobacterium
tumefaciens
0.75–1.99µg/g Cui et al. (300)
Nicotiana
benthamiana
Ebola virus GP1 IgG Agrobacterium
tumefaciens
0.4–0.5 mg/g Huang et al. (301)
Transgenic animals
Mouse HBV IgG Milk 17.8 mg/mL Zhang et al. (302)
Mouse CD147 Chimeric IgG Milk 1.1–7.4 mg/mL Wei et al. (303)
Mouse Hepatitis A virus IgG Milk 32 mg/mL Zhang et al. (304)
Mouse HER2 scFv-Fc Milk ∼120 ng/mL Yuskevich et al. (305)
Chicken CD2, prion peptide Chimeric IgG Egg white <150µg/mL Kamihira et al. (306)
AaHI, toxin class I of Androctonus australis hector scorpion venom; BoNT/A, Bolutinum toxin serotype A; CPMV, cowpea mosaic virus; FAP, fibroblast activation
protein alpha; HCC, hepatocellular carcinoma; phOx, 2-phenyl-oxazoline-5on; PEI, polyethyleneimine; PPL, peptostreptococcal protein L; RhD, rhesus factor D; uPA,
urokinase type plasminogen activator.
pattern does not play a critical role, such as for in vitro diagnos-
tics or in research. Therefore, bacteria, yeasts, filamentous fungi,
and insect cells can be employed in order to lower the production
costs of these products. In principle, transgenic plants and animals
have the highest potential for up-scaling processes to theoretically
unlimited production amounts. An overview of recombinant anti-
bodies produced in different hosts is shown in Table 1. There,
however, it must be discriminated between the yield of functional
antibodies after purification and the total yield.
Antibody phage display is now a widespread method for the
development of antibody fragments such as scFv or Fab. The
expression host used in this technology is E. coli which is known
to be the best genetically examined organism providing a large
set of molecular biological tools for genetical engineering. Con-
sequently, both antibody generation and production can be per-
formed without changing the production system. Using high-cell
density fermentation, the yield can be up to 1–2 g/L depending on
the individual antibody fragment. Antibody fragments expressed
in E. coli are mainly secreted into the periplasm and have to be
extracted from there. Gram-positive bacteria lack the outer mem-
brane and are well suited for biotechnological processes due to
their powerful secretion apparatus which allow easy purification
directly from the cultivation supernatant. However, antibody pro-
duction systems employing Gram-positive bacteria are still in the
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developmental stage. However, larger antibody formats are very
difficult to express in bacteria, if they can be expressed at all. Fur-
thermore, the lack of a glycosylation apparatus limits their use, if
effector functions are needed.
Yeasts, as an eukaryotic organism, has the capacity to perform
post-translational modifications. In addition, they can be used
even in high throughput processes and glyco-engineering enables
the expression of recombinant proteins with human-like glycosy-
lation. Nevertheless, the production of full-size immunoglobulins
remains a challenge. Compared to yeasts, filamentous fungi are
more difficult for the generation of transformed clones, but they
have a long tradition for the usage in biotechnology and they
have partially been used for the expression of IgGs. In contrast,
the development of protozoa as an expression system for recom-
binant proteins and antibodies has just been started and is still
in a developmental stage. However, the mammalian-like glycosy-
lation pattern presents them a promising candidate for further
exploitation.
Insect cells contain a better suited protein folding and secretion
apparatus than prokaryotes. Their high robustness combined with
less sophisticated requirements for fermentation provide some
advantages compared to mammalian cells. However, the devel-
opment of stable insect cell lines and process technology is not
developed as far. Consequently, mammalian cell lines are most
widely used for the production of therapeutic antibodies as they
provide a sophisticated folding and secretion apparatus as well
as human-like glycosylation. For the production of high levels of
recombinant antibodies high technical efforts are needed leading
to relatively high costs. The maximum reported yield of functional
IgG was 5 g/L which cannot be achieved using other expression sys-
tems so far, but up-scaling of the production does not lead to a
high reduction of the production costs.
For an efficient reduction of production costs, transgenic plants
can be used as they represent a highly scalable expression sys-
tem; cultivation can be easily expanded without a gross increase
in costs. In contrast, the generation of transgenic plants remains
very complex and difficult. The most important obstacle of trans-
genic plants is the downstream processing as tons of plant mate-
rial may have to be processed. However, antibody production in
milk or eggs of animals would also be highly scalable and per-
mits easy downstream processing. Several livestock animal species
have been developed for the expression of recombinant proteins,
but generation of transgenic animals also is very laborious. An
interesting approach is the combination of human transgenic ani-
mals with hybridoma technology for the development of human
antibodies.
In principle, there is no “universal” production system which
can guarantee high yields of recombinant antibody, particularly as
every antibody-based molecule itself will cause its own issues in
terms of expression.
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